Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
- DOI
- 10.1016/j.jiac.2022.03.002
- Published
- 2022 Jul
- Container
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jiac.2022.03.002,
title = {Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.},
author = {Miyazato Y and Yamamoto K and Nakaya Y and Morioka S and Takeuchi JS and Takamatsu Y and Maeda K and Kimura M and Sugiura W and Mitsuya H and Yano M and Ohmagari N},
year = {2022},
journal = {Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy},
doi = {10.1016/j.jiac.2022.03.002},
url = {https://doi.org/10.1016/j.jiac.2022.03.002}
}RIS
TY - JOUR TI - Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19. AU - Miyazato Y AU - Yamamoto K AU - Nakaya Y AU - Morioka S AU - Takeuchi JS AU - Takamatsu Y AU - Maeda K AU - Kimura M AU - Sugiura W AU - Mitsuya H AU - Yano M AU - Ohmagari N PY - 2022 JO - Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy DO - 10.1016/j.jiac.2022.03.002 UR - https://doi.org/10.1016/j.jiac.2022.03.002 ER -
APA
Y, M., K, Y., Y, N., S, M., JS, T., Y, T., K, M., M, K., W, S., H, M., M, Y., & N, O. (2022). Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. https://doi.org/10.1016/j.jiac.2022.03.002
Source records
- pubmed · retrieved 2026-09-27T10:03:24.989Z